Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...

NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company’s ...

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

NeoGenomics (NEO) has recently drawn investor attention without a single headline catalyst, as its share price, recent returns and current fundamentals in cancer-focused diagnostics invite closer ...

FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has ...

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next ...

NeoGenomics shows strong clinical revenue growth and positive technical momentum, but faces significant profitability and cash flow challenges. The valuation remains a concern due to negative earnings ...

(NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company ...

New ctDNA-based test offers a flexible, guideline-driven solution for patients with advanced solid tumors when tissue is limited or unavailable “The launch of our liquid biopsy test positions us at ...